Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blinded, and Placebo-controlled Phase I/II Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Trial Profile

A Randomized, Double-blinded, and Placebo-controlled Phase I/II Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AK-101 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Akeso Biopharma
  • Most Recent Events

    • 19 Nov 2019 Status changed from recruiting to completed.
    • 21 Mar 2018 New trial record
    • 22 Dec 2017 According to an Akeso Biopharma media release, this trial has been launched at the Chinese Academy of Medical Sciences Peking Union Medical College Hospital, and has begun screening and enrolling patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top